论文部分内容阅读
目的对奥扎格雷钠联合依达拉奉治疗急性脑梗死的临床疗效及安全性进行评价。方法 106例急性脑梗死患者随机分为2组,治疗组53例,在常规支持疗法基础上采用奥扎格雷钠+依达拉奉治疗;对照组53例,除不使用依达拉奉和奥扎格雷钠外,其他同治疗组。结果治疗组有效率为90.57%,明显高于对照组的77.36%,两组比较P<0.05。在用药过程及疗程后复查血尿常规、肝肾功能检查,未发现明显不良应。结论奥扎格雷钠联合依达拉奉治疗急性脑梗死安全、有效,值得临床推广。
Objective To evaluate the clinical efficacy and safety of ozagrel combined with edaravone in the treatment of acute cerebral infarction. Methods One hundred and sixty patients with acute cerebral infarction were randomly divided into two groups: treatment group (n = 53) and ozagrel sodium plus edaravone (n = 53). Control group (n = 53) Zagre sodium, the other with the treatment group. Results The effective rate of the treatment group was 90.57%, which was significantly higher than that of the control group (77.36%), P <0.05. In the course of medication and after treatment review of hematuria, liver and kidney function tests, no significant adverse reactions should not be found. Conclusion Ozagrel combined with edaravone in the treatment of acute cerebral infarction is safe and effective, which is worthy of clinical promotion.